Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTSW), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. develops Alpha DaRT, an alpha-radiation cancer therapy designed for localized treatment of solid tumors through intratumoral delivery of radium-224 impregnated sources. News about the company centers on clinical programs in recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, prostate cancer, and head and neck cancer, along with presentations of study data at oncology and gastroenterology meetings.
Recurring updates also cover regulatory activity for Alpha DaRT, including FDA pre-market approval materials, Breakthrough Device Designation references, and Japanese marketing approval for unresectable locally advanced or locally recurrent head and neck cancer. Other company news addresses financial results, corporate updates, manufacturing preparation, and investor conference presentations.
Alpha Tau Medical Ltd. (Nasdaq: DRTS) announced the resignation of Peter Melnyk from the Board of Directors to assume the role of Chief Commercial Officer. Melnyk brings extensive experience in oncology from prior roles at Fortovia Therapeutics, Novocure, and OSI Pharmaceuticals. CEO Uzi Sofer expressed confidence that Melnyk will enhance Alpha Tau's commercialization efforts, particularly as the company seeks further marketing approvals for its Alpha DaRT cancer therapy, with a critical U.S. study on recurrent squamous cell carcinoma starting soon.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced participation in three investor conferences in September 2022. The events include Citi's 17th Annual BioPharma Conference on September 7 in Boston, MA, the Cantor Oncology, Hematology & HemeOnc Conference on September 28 in New York, NY, and the Ladenburg Thalmann Annual Healthcare Conference on September 29 in New York, NY. Each conference will feature 1:1 meetings and presentations to discuss Alpha Tau's innovative alpha-radiation cancer therapy, Alpha DaRT™, aimed at treating solid tumors.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced FDA approval for a pivotal trial of its Alpha DaRT™ therapy in recurrent cutaneous squamous cell carcinoma, expecting to treat the first patient in late 2022. The company also initiated a feasibility study in prostate cancer. Financially, R&D expenses rose to $5.4 million, while the net loss narrowed to $2.0 million or ($0.03) per share. Cash reserves increased significantly to $112.8 million, projected to sustain operations for at least two years. The company aims to expand its treatment pipeline to more invasive cancers, including pancreatic and GBM.
On March 28, 2022, Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) reported its 2021 financial results, highlighting a significant 100% complete response rate in its U.S. pilot trial for skin cancer. The company received two FDA breakthrough device designations and successfully completed its merger with Healthcare Capital Corp, raising approximately $90 million. R&D expenses increased to $11.4 million, resulting in a net loss of $27.3 million for the year. As of December 31, 2021, Alpha Tau's cash reserves stood at $31.9 million, expected to sustain operations for two years.